In vitro studies on metabolism of salvinorin A

References

• Abourashed EA, Clark AM, Huford CD (1999): Microbial models of mammalian metabolism of xenobiotics: An updated review. Curr Med Chem 6: 359–374.
   PubMed Web of Science ®Google Scholar
• Allt G, Lawrenson JG (2000): The blood-nerve barrier: enzymes, transporters and receptors – a comparison with the blood-brain barrier. Brain Res Bull 52: 1–12.
   PubMedGoogle Scholar
• Babu KM, McCurdy CR, Boyer EW (2008): Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol 46: 146–152.
   PubMed Web of Science ®Google Scholar
• Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WAJ (2008): Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33: 2550–2562.
   Google Scholar
• Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004): Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. J Pharmacol Exp Ther 308: 1197–1203.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989): Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695–698.
   PubMed Web of Science ®Google Scholar
• El Sayed KA, Hamann MT, Waddling CA, Jensen CL, Sang K, Dunstan CA, Pezzuto JM (1998): Structurally novel bioconversion products of the marine natural product sarcophine effectively inhibit JB6 cell transformation. J Org Chem 63: 7449–7455.
   PubMed Web of Science ®Google Scholar
• Giner JL, Kiemle DJ, Kutrzeba L, Zjawiony JK (2007): Unambiguous NMR spectral assignments of salvinorin A. Magn Reson Chem 45: 351–354.
   PubMedGoogle Scholar
• Hanson JR (1992): The microbiological transformation of diterpenoids. Nat Prod Rep 9: 139–151.
   PubMed Web of Science ®Google Scholar
• Mello NK, Negus SS (2000): Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann NY Acad Sci 909: 104–132.
   PubMed Web of Science ®Google Scholar
• Miyazawa M, Kawazoe H, Hyakumachi M (2003): Biopreparation of (–)-(1S,3R,4S,6S)-6-hydroxymenthol and (–)-(1S,3R,4S)-1- hydroxymenthol from 1-menthol by Rhizoctonia solani AG-1-IA and IB. Nat Prod Res 17: 307–311.
   PubMed Web of Science ®Google Scholar
• Orabi KY, Li E, Clark AM, Hufford CD (1999): Microbial transformation of sampangine. J Nat Prod 6: 988–992.
   Google Scholar
• Parshikov IA, Miriyala B, Muraleedharan KM, Avery MA, Williamson JS (2006): Microbial transformation of artemisinin to 5-hydroxyartemisinin by Eurotium amstelodami and Aspergillus niger. J Ind Microbiol Biotechnol 33: 349–352.
   PubMedGoogle Scholar
• Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R, Torre RD, Zuccaro P (2005): Quantification of the plant-derived hallucinogen salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 19: 1649–1656.
   PubMed Web of Science ®Google Scholar
• Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002): Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci USA 99: 11934–11939.
   PubMed Web of Science ®Google Scholar
• Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, Prisinzano TE (2005a): Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58: 208–210.
   PubMed Web of Science ®Google Scholar
• Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ, Murry DJ (2005b): Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B 818: 221–225.
   PubMed Web of Science ®Google Scholar
• Sebek OK (1982): Microbial models of mammalian metabolism. In: Rosazza JP, ed., Microbial Transformation of Bioactive Compounds. Boca Raton, FL, CRC Press, pp. 1–8.
   Google Scholar
• Sheffler DJ, Roth BL (2003): Salvinorin A: The “magic mint” hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24: 107–109.
   PubMed Web of Science ®Google Scholar
• Stabler PJ, Holt PJ, Bruce NC (2001): Transformation of 2,2′-bimorphine to the novel compounds 10-α-S-monohydroxy-2,2′-bimorphine and 10,10′-α,α′-S,S′-dihydroxy-2,2′-bimorphine by Cylindrocarpon didymum. Appl Environ Microbiol 67: 3716–3719.
   PubMedGoogle Scholar
• Valdes LJ, Diaz JL, Paul AG (1983): Ethnopharmacology of Ska Maria Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol 7: 287–312.
   PubMed Web of Science ®Google Scholar
• Venisetty RK, Ciddi V (2003): Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr Pharm Biotechnol 4: 153–167.
   PubMedGoogle Scholar
• Wang Y, Chen Y, Xu W, Lee DYW, Ma Z, Rawls SM, Cowan A, Liu-Chen, Lee-Yuan (2008): 2-Methoxymethyl-salvinorin B is a potent κ-opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 324:1073–1083.
   PubMedGoogle Scholar